(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Figure out How to Assess the Unwavering quality of SUVs for Seniors - 2Brexit's Effect on New York's Ascent as a Main Monetary Center
- 3'Stranger Things' Season 5: When does Volume 2 come out? And Volume 3? Everything to know about the remaining episodes before the finale.
- 4Illustrations Gained from a Crosscountry Excursion
- 5Wedding trip Objections in the US
- Extreme Manual for Picking a Camper Van
- Which camera do you believe is great for first-time clients? !
- Merck sees over $5 billion opportunity in Cidara's experimental flu drug
- 10 Hints and Deceives to Expand Cell Phone Information Use: Capitalize on Your Information
- Happy with Running Shoes for 2024
- 25 of the world’s best sandwiches
- Top Fascinating Organic products: Which One Might You Want to Attempt?
- Pick Your Favored kind of soup
- Most loved Caf\u00e9 Chain: Where Do You Get Your Caffeine Fix
